NEW YORK--(EON: Enhanced Online News)--Precision Biologics is pleased to announce the addition of Duke University Medical Center as a collaborator on its ongoing Phase 2b clinical trial with its lead therapeutic compound NPC-1C (NEO-102). The addition of Duke will parallel and compliment patient enrollment currently underway at both the National Cancer Institute, Bethesda, MD and Montefiore Medical Center, Bronx, NY (the University Hospital for Albert Einstein Medical School). This ongoing study is currently treating patients with the monoclonal antibody NPC-1C that targets a variant MUC-5ac that is expressed in the tumor of patients with pancreatic cancer. The study will enroll patients who have progressed on front line chemotherapy with Folfirinox. This Phase 2B study is designed to evaluate the efficacy of combining NPC-1C, with the chemotherapy drug Gemcitabine.
Dr. Philip M. Arlen, CEO and Chief Medical Officer of Precision Biologics, said, "There is a strong need for developing novel drugs for the treatment of patients with pancreatic cancer. We look forward to continuing our relationship with the investigators at Duke University in the clinical development of NPC-1C. Furthermore, we are encouraged that this collaboration will lead to accelerated patient enrollment with an opportunity for improved outcomes by combining NPC-1C with Gemcitabine based chemotherapy."
Precision Biologics: http://www.precision-biologics.com/
Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials.